Saad ED - Search Results

1

Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.

Coart E, Suciu S, Squifflet P, Saad ED, Moshyk A, de Schaetzen G, Buyse M, Weber JS, Eggermont A, Kotapati S. Coart E, et al. Among authors: saad ed. Eur J Cancer. 2020 Sep;137:171-174. doi: 10.1016/j.ejca.2020.07.011. Epub 2020 Aug 7. Eur J Cancer. 2020. PMID: 32777716

2

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.

Saad ED, Katz A, Hoff PM, Buyse M. Saad ED, et al. Ann Oncol. 2010 Jan;21(1):7-12. doi: 10.1093/annonc/mdp523. Epub 2009 Nov 9. Ann Oncol. 2010. PMID: 19901012 Free article. Review.

3

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.

Saad ED, Katz A, Buyse M. Saad ED, et al. J Clin Oncol. 2010 Apr 10;28(11):1958-62. doi: 10.1200/JCO.2009.25.5414. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194852 Review.

4

[Overall survival and other clinical outcomes in breast cancer :current situation and controversies].

Machado KK, Katz A, Buyse M, Saad ED. Machado KK, et al. Among authors: saad ed. Rev Assoc Med Bras (1992). 2010 Sep-Oct;56(5):514-6. doi: 10.1590/s0104-42302010000500008. Rev Assoc Med Bras (1992). 2010. PMID: 21152819 Free article. Review. Portuguese. No abstract available.

5

Survival is not a good outcome for randomized trials with effective subsequent therapies.

Buyse M, Sargent DJ, Saad ED. Buyse M, et al. Among authors: saad ed. J Clin Oncol. 2011 Dec 10;29(35):4719-20; author reply 4720-1. doi: 10.1200/JCO.2011.38.4206. Epub 2011 Oct 31. J Clin Oncol. 2011. PMID: 22042965 No abstract available.

6

Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?

Saad ED, Buyse M. Saad ED, et al. J Clin Oncol. 2012 May 20;30(15):1750-4. doi: 10.1200/JCO.2011.38.6359. Epub 2012 Mar 5. J Clin Oncol. 2012. PMID: 22393092 No abstract available.

7

Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects.

Saad ED, Buyse M. Saad ED, et al. Acta Oncol. 2012 Sep;51(7):890-6. doi: 10.3109/0284186X.2012.702924. Acta Oncol. 2012. PMID: 22974094

8

Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.

Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M, Taylor RS. Ciani O, et al. Among authors: saad ed. Int J Technol Assess Health Care. 2014 Jul;30(3):312-24. doi: 10.1017/S0266462314000300. Int J Technol Assess Health Care. 2014. PMID: 25308694 Free article. Review.

9

Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.

Ciani O, Buyse M, Garside R, Peters J, Saad ED, Stein K, Taylor RS. Ciani O, et al. Among authors: saad ed. J Clin Epidemiol. 2015 Jul;68(7):833-42. doi: 10.1016/j.jclinepi.2015.02.016. Epub 2015 Mar 6. J Clin Epidemiol. 2015. PMID: 25863582 Free article. Review.

10

Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.

Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M. Squifflet P, et al. Among authors: saad ed. Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):680-6. doi: 10.1016/j.clml.2015.09.005. Epub 2015 Sep 25. Clin Lymphoma Myeloma Leuk. 2015. PMID: 26482107

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters